124.34EUR-1.55%Mkt Cap: 168.53B $P/E: —1d ago
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, D…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
Company
Market Cap168.53B $
Enterprise Value189.74B $
Revenue (TTM)33.11B $
Gross Profit25.23B $
Net Income (TTM)9.25B $
Revenue/Share26.64 USD
Last Price124.34 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17.0K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS3755581036
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG2.15
EV/EBITDA11.96
EV/Revenue5.73
P/S5.03
P/B7.54
EPS (TTM)-2.29
EPS (Forward)—
52W Range
119.8460% of range127.34
52W High127.34 EUR
52W Low119.84 EUR
Profitability
Gross Margin78.83%
Oper. Margin33.68%
EBITDA Margin47.94%
Profit Margin28.90%
ROE37.49%
ROA14.42%
Growth
Revenue Growth10.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF10.89B $
CapEx (TTM)611.96M $
FCF Margin32.07%
FCF Yield6.30%
Net Debt23.22B $
Net Debt/EBITDA1.46
Balance Sheet
Debt/Equity1.10
Current Ratio1.26
Quick Ratio0.90
Book Value/Sh16.40 EUR
Cash/Share3.937 EUR
Dividends
Fwd Div Rate2.850 EUR
Trail. Div Rate3.220 EUR
Div. Yield2.38%
5Y Avg Yield3.55%
Payout Ratio43.40%
Ex-Div DateSep 15, 2026
Pay Date—
Splits
Last Split2:1
Split DateJan 28, 2013
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.24B
Float1.24B
Insiders0.11%
Institutions92.57%
Technical
SMA 50113.42 (+9.6%)
SMA 200114.39 (+8.7%)
Beta0.34
S&P 52W Chg20.80%
Avg Vol (30d)1.39K
Avg Vol (10d)1.06K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—